This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Pfizer Inc.
Reference
Wilson M, et al. Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada. Infectious Diseases and Therapy : 22 Jun 2018. Available from: URL: https://doi.org/10.1007/s40121-018-0206-1
Rights and permissions
About this article
Cite this article
13-Valent pneumococcal conjugate vaccine better value for money. PharmacoEcon Outcomes News 807, 3 (2018). https://doi.org/10.1007/s40274-018-5082-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5082-0